Understanding resistance to EGFR inhibitors—impact on future treatment strategies

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Untangling the ErbB signalling network

Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R. K., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,109

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877

RasGRP1 is a potential biomarker for stratifying anti-EGFR therapy response in colorectal cancer

Gbenedio, O. M., Bonnans, C., Grün, D., Wang, C., Hatch, A. J., Mahoney, M. R., Barras, D., Matli, M. R., Miao, Y., García, K. C., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127552 · Cited by 26

Phenethyl isothiocyanate synergistically induces apoptosis with Gefitinib in non–small cell lung cancer cells via endoplasmic reticulum stress‐mediated degradation of Mcl‐1

Zhang, Q., Chen, M., Cao, L., Ren, Y., Guo, X., Wu, X., & Xu, K. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23184 · Cited by 26

An Ex Vivo Human Tumor Assay Shows Distinct Patterns of EGFR Trafficking in Squamous Cell Carcinoma Correlating to Therapeutic Outcomes

Joseph, S. R., Gaffney, D. C., Barry, R. E., Hu, L., Banushi, B., Wells, J. W., Lambie, D., Strutton, G., Porceddu, S. V., Burmeister, B. H., et al. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.06.190 · Cited by 25

Vorinostat enhances gefitinib‑induced cell death through reactive oxygen species‑dependent cleavage of HSP90 and its clients in non‑small cell lung cancer with the EGFR mutation

Park, S. G., Kim, D., Kim, M. K., Lee, J., Rho, J. K., Jeong, S., Choi, E., Kim, C., & Hwang, J. S. (2018) · Oncology Reports · doi:10.3892/or.2018.6814 · Cited by 25

Cell Derived Matrix Fibulin-1 Associates With Epidermal Growth Factor Receptor to Inhibit Its Activation, Localization and Function in Lung Cancer Calu-1 Cells

Harikrishnan, K., Joshi, O., Madangirikar, S., & Balasubramanian, N. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00522 · Cited by 25

Dual Inhibition of EGFR and IGF-1R Signaling Leads to Enhanced Antitumor Efficacy against Esophageal Squamous Cancer

Kang, J., Guo, Z., Zhang, H., Guo, R., Zhu, X., & Guo, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810382 · Cited by 27

Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells

Furugaki, K., Iwai, T., Moriya, Y., Harada, N., & Fujimoto-Ouchi, K. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.10.003 · Cited by 25

3q26‐29 Amplification in head and neck squamous cell carcinoma: a review of established and prospective oncogenes

Davidson, M. A., & Shanks, E. (2017) · The FEBS Journal · doi:10.1111/febs.14061 · Cited by 23

Screening of epidermal growth factor receptor inhibitors in natural products by capillary electrophoresis combined with high performance liquid chromatography–tandem mass spectrometry

Li, F., Zhang, Y., Qiu, D., & Kang, J. (2015) · Journal of Chromatography A · doi:10.1016/j.chroma.2015.04.055 · Cited by 25

Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFRT790M mutant cell lines

Zhao, L., Fan, T., Shi, Z., Ding, C., Zhang, C., Yuan, Z., Sun, Q., Tan, C., Chu, B., & Jiang, Y. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113173 · Cited by 24

Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep‐2 cancer cells

Bianchi, L., Bruzzese, F., Leone, A., Gagliardi, A., Puglia, M., Gennaro, E. D., Rocco, M., Gimigliano, A., Pucci, B., Armini, A., et al. (2011) · PROTEOMICS · doi:10.1002/pmic.201100092 · Cited by 24

Targeting of the epidermal growth factor receptor with mesoporphyrin IX-peptide conjugates

Fontenot, K. R., Ongarora, B. G., LeBlanc, L. E., Zhou, Z., Jois, S. D. S., & Vicente, M. G. H. (2016) · Journal of Porphyrins and Phthalocyanines · doi:10.1142/s1088424616500115 · Cited by 24

Recent Development of the Second and Third Generation Irreversible Epidermal Growth Factor Receptor Inhibitors

Han, W., & Du, Y. (2017) · Chemistry & Biodiversity · doi:10.1002/cbdv.201600372 · Cited by 24

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy

Lucia, A. D., Mazzotti, L., Gaimari, A., Zurlo, M., Maltoni, R., Cerchione, C., Bravaccini, S., Delmonte, A., Crinò, L., de Souza, P. B., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1515748 · Cited by 25

The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitors

Wainberg, Z. A., & Drakaki, A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1050375 · Cited by 23

Activation of Focal Adhesion Kinase and Src Mediates Acquired Sorafenib Resistance in A549 Human Lung Adenocarcinoma Xenografts

Zhou, Q. S., Guo, X., & Choksi, R. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.240507 · Cited by 23

Advances in molecular targeted therapies to increase efficacy of (chemo)radiation therapy

Viktorsson, K., Rieckmann, T., Fleischmann, M., Diefenhardt, M., Hehlgans, S., & Rödel, F. (2023) · Strahlentherapie und Onkologie · doi:10.1007/s00066-023-02064-y · Cited by 29

Recombinant IgE antibody engineering to target EGFR

Spillner, E., Plum, M., Blank, S., Miehe, M., Singer, J., & Braren, I. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1287-4 · Cited by 26

EGFR blockade in GBM brain tumor stem cells synergizes with JAK2/STAT3 pathway inhibition to abrogate compensatory mechanisms in vitro and in vivo

Jensen, K. V., Hao, X., Aman, A. M., Luchman, H. A., & Weiss, S. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa020 · Cited by 23

The prospect of substrate-based kinase inhibitors to improve target selectivity and overcome drug resistance

Biswas, B., Huang, Y., Craik, D. J., & Wang, C. K. L. (2024) · Chemical Science · doi:10.1039/d4sc01088d · Cited by 25

Collateral sensitivity of drug-resistant ABCB5- and mutation-activated EGFR overexpressing cells towards resveratrol due to modulation of SIRT1 expression

Saeed, M. E. M., Rahama, M. S., Kuete, V., Dawood, M., Elbadawi, M., Sugimoto, Y., & Efferth, T. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.152890 · Cited by 22

Annexin A6 improves anti‐migratory and anti‐invasive properties of tyrosine kinase inhibitors in EGFR overexpressing human squamous epithelial cells

Hoque, M., Elmaghrabi, Y. A., Köse, M., Beevi, S. S., Jose, J., Meneses‐Salas, E., Blanco‐Muñoz, P., Conway, J. R. W., Swarbrick, A., Timpson, P., et al. (2019) · FEBS Journal · doi:10.1111/febs.15186 · Cited by 22

Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells

Saha, N., Xu, K. Y., Zhu, Z., Tzvetkova‐Robev, D., Kalidindi, T. M., Xu, Y., Himanen, J. P., de Stanchina, E., Pillarsetty, N., Dimitrov, D. S., et al. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101265 · Cited by 22

Tyrosine dephosphorylation enhances the therapeutic target activity of epidermal growth factor receptor (EGFR) by disrupting its interaction with estrogen receptor (ER)

Shao, M., Yin, N. B., Qi, X.-M., Pfister, S. L., Zhang, M., Ma, R., & Chen, G. (2015) · Oncotarget · doi:10.18632/oncotarget.3645 · Cited by 22

IC-4, a new irreversible EGFR inhibitor, exhibits prominent anti-tumor and anti-angiogenesis activities

Li, Y., Wang, Z., Yan, X., Chen, M., Bao, J.-L., Wu, G., Ge, Z., Zhou, D., Wang, Y., & Li, R. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.07.005 · Cited by 22

A targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cells

Giordano, C. R., Mueller, K. L., Terlecky, L. J., Krentz, K. A., Bollig-Fischer, A. B., Terlecky, S. R., & Boerner, J. L. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.06.001 · Cited by 23

Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN)

Price, K. A. R., & Cohen, E. E. W. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2015.01.018 · Cited by 22

Aptamer technology for tracking cells’ status & function

Wiraja, C., Yeo, D., Lio, D. C. S., Labanieh, L., Lu, M., Zhao, W., & Xu, C. (2014) · Molecular and Cellular Therapies · doi:10.1186/2052-8426-2-33 · Cited by 21

Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux�) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models

Menéndez, J. A. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1155 · Cited by 22

Small Molecule T315 Promotes Casitas B-Lineage Lymphoma–Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation

Huang, K., Kao, S.-H., Wang, W.-L., Chen, C., Hsiao, T.-H., Salunke, S. B., Chen, J. J. W., Su, K., Yang, S., Hong, T.-M., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201502-0250oc · Cited by 23

The correlation between FDG uptake and biological molecular markers in pancreatic cancer patients

Kaida, H., Azuma, K., Kawahara, A., Yasunaga, M., Kitasato, Y., Hattori, S., Taira, T., Ureshino, H., Kage, M., Ishii, K., et al. (2016) · European Journal of Radiology · doi:10.1016/j.ejrad.2016.08.007 · Cited by 22

NF-κB activation is an early event of changes in gene regulation for acquiring drug resistance in human adenocarcinoma PC-9 cells

Fukuoka, M., Yoshioka, K., & Hohjoh, H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201796 · Cited by 22

Dysregulated Redox Regulation Contributes to Nuclear EGFR Localization and Pathogenicity in Lung Cancer

Little, A. C., Hristova, M., van Lith, L., Schiffers, C., Dustin, C. M., Habibovic, A., Danyal, K., Heppner, D. E., Lin, M.-C. J., van der Velden, J. L. J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41395-8 · Cited by 22

Digital pathology in personalized cancer therapy

Janina Slodkowska, C., & Rojo, M. G. (2012) · Folia Histochemica et Cytobiologica · doi:10.5603/fhc.2011.0080 · Cited by 22

Platinum-based targeted chemotherapies and reversal of cisplatin resistance in non-small cell lung cancer (NSCLC)

Umar, H., Wahab, H. A., Attiq, A., Amjad, M. W., Bukhari, S. N. A., & Ahmad, W. (2024) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2024.111856 · Cited by 23

ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor

Juliachs, M., Castillo, W., Vidal, A., Piulats, J. M., del Muro, X. G., Condom, E., Hernández‐Losa, J., Teixidó, C., Pandiella, A., Graupera, M., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28009 · Cited by 22

High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis

Wang, C.-Y., Deng, J., Cai, X.-W., Fu, X., Li, Y., Zhou, X.-Y., Wu, X.-H., Hu, X., Fan, M., Xiang, J.-Q., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4367 · Cited by 21

3,6,2′,4′,5′-Pentahydroxyflavone, an Orally Bioavailable Multiple Protein Kinase Inhibitor, Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer

Sheng, Y., Li, W., Zhu, F., Liu, K., Chen, H., Yao, K., Reddy, K., Lim, D. Y., Oi, N., Li, H., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.593475 · Cited by 21

Overcoming Molecular Mechanisms of Resistance to First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Bar, J., & Onn, A. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.09.001 · Cited by 21

Clinical significance of blood‑based miRNAs as biomarkers of non‑small cell lung cancer (Review)

Li, L., Sun, Y., Feng, M., Wang, L., & Liu, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.8469 · Cited by 21

Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients—Analysis of the Phase III AIO KRK-0207 Trial

Stintzing, S., Ivanova, B., Ricard, I., Jung, A., Kirchner, T., Tannapfel, A., Juette, H., Hegewisch‐Becker, S., Arnold, D., & Reinacher‐Schick, A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00474 · Cited by 23

Optimization of gefitinib analogues with potent anticancer activity

Yin, K.-H., Hsieh, Y.-H., Sulake, R. S., Wang, S., Chao, J., & Chen, C. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.09.056 · Cited by 21

Cellular and molecular properties of 90Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro

Saki, M. R., Toulany, M., Sihver, W., Zenker, M., Heldt, J., Mosch, B., Pietzsch, H., Baumann, M. A., Steinbach, J., & Rodemann, H. P. (2012) · Strahlentherapie und Onkologie · doi:10.1007/s00066-012-0121-4 · Cited by 20

AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer

Iida, M., McDaniel, N. K., Kostecki, K. L., Welke, N. B., Kranjac, C. A., Liu, P., Longhurst, C. A., Bruce, J. Y., Hong, S., Salgia, R., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09511-6 · Cited by 21

CBX5 loss drives EGFR inhibitor resistance and results in therapeutically actionable vulnerabilities in lung cancer

Bugide, S., Edwards, Y. J. K., Gupta, R., Green, M. R., & Wajapeyee, N. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2218118120 · Cited by 21

Metabolomics analysis reveals aminoquinazolin derivative 9d-induced oxidative stress and cell cycle arrest in A549 cells

Liu, W., Jin, F., Gao, D., Song, L., Ding, C., & Liu, H. (2017) · RSC Advances · doi:10.1039/c7ra00185a · Cited by 20

Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer

Nair, S., Trummell, H. Q., Rajbhandari, R., Thudi, N. K., Nozell, S. E., Warram, J. M., Willey, C. D., Yang, E. S.-H., Placzek, W. J., Bonner, J. A., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229077 · Cited by 21

Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer

Liao, Z., Huang, K., Kempson, I. M., Li, H., Tseng, S. ‐., & Yang, P. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.043 · Cited by 20

111In-Cetuximab-F(ab′)2 SPECT and 18F-FDG PET for Prediction and Response Monitoring of Combined-Modality Treatment of Human Head and Neck Carcinomas in a Mouse Model

van Dijk, L. K., Boerman, O. C., Franssen, G. M., Kaanders, J. H. A. M., & Bussink, J. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.148296 · Cited by 20

“Chronic” metastatic pancreatic acinar cell carcinoma

Cananzi, F., Jayanth, A., Lorenzi, B., Belgaumkar, A. P., Mochlinski, K., Sharma, A., Mudan, S., & Cunningham, D. (2013) · Pancreatology · doi:10.1016/j.pan.2013.05.001 · Cited by 19

Integration of pharmacophore-based virtual screening, molecular docking, ADMET analysis, and MD simulation for targeting EGFR: A comprehensive drug discovery study using commercial databases

Alanzi, A. R., Moussa, A. Y., Alsalhi, M. S., Nawaz, T., & Ali, I. (2024) · PLoS ONE · doi:10.1371/journal.pone.0311527 · Cited by 19

Autocrine Proliferative Effects of hGH Are Maintained in Primary Cultures of Human Mammary Carcinoma Cells

Chiésa, J., Ferrer, C., Arnould, C., Vouyovitch, C. M., Diaz, J., Gonzalez, S., Marès, P., Morel, G., Wu, Z., Zhu, T., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0473 · Cited by 19

Early Assessment of Tumor Response to Gefitinib Treatment by Noninvasive Optical Imaging of Tumor Vascular Endothelial Growth Factor Expression in Animal Models

Liu, Z., Sun, X., Liu, H., Ma, T., Shi, J., Jia, B., Zhao, H., & Wang, F. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.133660 · Cited by 19

The Epidermal Growth Factor Receptor (EGFR / HER-1) Gatekeeper Mutation T790M Is Present in European Patients with Early Breast Cancer

Bemanian, V., Sauer, T., Touma, J., Lindstedt, B.-A., Chen, Y., Ødegård, H. P., Vetvik, K. M., Bukholm, I., & Geisler, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134398 · Cited by 19

Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW 479, by down‐regulating EGFR expression

Li, J., Zhang, T., Yang, F., He, Y., Dai, F., Gao, D., Chen, Y., Liu, M., & Yi, Z. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13165 · Cited by 19

The paradigm of personalized therapy in oncology

Gasparini, G., & Longo, R. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.637921 · Cited by 18

BAG3‐dependent expression of Mcl‐1 confers resistance of mutant KRAS colon cancer cells to the HSP90 inhibitor AUY922

Wang, C. Y., Guo, S., Croft, A. J., Yan, X. G., Jin, L., Zhang, X. D., & Jiang, C. C. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22755 · Cited by 18

SHC1 Promotes Lung Cancer Metastasis by Interacting with EGFR

Yang, P., Li, W., & Li, X. (2022) · Journal of Oncology · doi:10.1155/2022/3599832 · Cited by 18

The development and benefits of metformin in various diseases

Dong, Y., Qi, Y., Jiang, H., Tian, M., Zhang, Y., Peng, C. S., Li, W.-C., Zhang, Y., Zhou, Y., Zang, Y., et al. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-0998-6 · Cited by 21

EGFR expression is linked to osteopontin and Nf-κB signaling in clear cell renal cell carcinoma

Matušan‐Ilijaš, K., Damante, G., Fabbro, D., Đorđević, G., Hadžisejdić, I., Grahovac, M., Avirović, M., Grahovac, B., Jonjić, N., & Lučin, K. (2012) · Clinical & Translational Oncology · doi:10.1007/s12094-012-0889-9 · Cited by 18

111In-cetuximab-F(ab’)2 SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts

van Dijk, L. K., Hoeben, B. A. W., Stegeman, H., Kaanders, J. H. A. M., Franssen, G. M., Boerman, O. C., & Bussink, J. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.06.034 · Cited by 18

PharmGKB summary

Hodoğlugil, U., Whirl‐Carrillo, M., Hebert, J. M., Karachaliou, N., Rosell, R., Altman, R. B., & Klein, T. E. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283655091 · Cited by 18

Development of certain aminoquinazoline scaffolds as potential multitarget anticancer agents with apoptotic and anti-proliferative effects: Design, synthesis and biological evaluation

Amin, N. H., El‐Saadi, M. T., Abdel‐Fattah, M. M., Mohammed, A. A., & Said, E. G. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106496 · Cited by 17

Dacomitinib, an emerging HER-targeted therapy for non-small cell lung cancer.

Carpenter, R. L., & Lo, H. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2012.10.09 · Cited by 17

Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds

Huang, Y., Chen, Y., MEI, Q., Chen, Y., Yu, S., & Xia, S. (2013) · Oncology Reports · doi:10.3892/or.2013.2357 · Cited by 17

Membranous Expression of Ectodomain Isoforms of the Epidermal Growth Factor Receptor Predicts Outcome after Chemoradiotherapy of Lymph Node–Negative Cervical Cancer

Halle, C., Lando, M., Svendsrud, D. H., Clancy, T., Holden, M., Sundfør, K., Kristensen, G. B., Holm, R., & Lyng, H. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0297 · Cited by 17

244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells

Zhang, Y., Yao, K., Shi, C., Jiang, Y., Liu, K., Zhao, S., Chen, H., Reddy, K., Zhang, C., Chang, X., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6236 · Cited by 17

CoGAPS matrix factorization algorithm identifies transcriptional changes in AP-2alpha target genes in feedback from therapeutic inhibition of the EGFR network

Fertig, E. J., Ozawa, H., Thakar, M., Howard, J. D., Kagohara, L. T., Krigsfeld, G. S., Ranaweera, R. S., Hughes, R. M., Pérez, J., Jones, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12075 · Cited by 16

Altered expression of cellular proliferation, apoptosis and the cell cycle-related genes in lung cancer cells with acquired resistance to EGFR tyrosine kinase inhibitors

Lee, T., Jeong, E., Min, I. J., Kim, S. Y., Kim, H.-R., & Kim, C. H. (2017) · Oncology Letters · doi:10.3892/ol.2017.6428 · Cited by 17

Anti-EGFR Binding Nanobody Delivery System to Improve the Diagnosis and Treatment of Solid Tumours

Wang, L., Zhang, G., Qin, L., Ye, H., Wang, Y., Long, B., & Jiao, Z. (2020) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892815666200904111728 · Cited by 17

EGF-induced sodium influx regulates EGFR trafficking through HDAC6 and tubulin acetylation

Lee, S. J., Li, Z., Litan, A., Yoo, S., & Langhans, S. A. (2015) · BMC Cell Biology · doi:10.1186/s12860-015-0070-8 · Cited by 17

Urokinase is a negative modulator of Egf‐dependent proliferation and motility in the two breast cancer cell lines MCF‐7 and MDA‐MB‐231

Kozlova, N., Samoylenko, A., Дробот, Л. Б., & Kietzmann, T. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22267 · Cited by 17

A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases

Wang, Y., Lee, H., & Hung, M. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0484-7 · Cited by 18

Winning the Arms Race by Improving Drug Discovery against Mutating Targets

Anderson, A. C. (2011) · ACS Chemical Biology · doi:10.1021/cb200394t · Cited by 16

Assessing the role of the EGF receptor in the development and progression of pancreatic cancer

Moore, M. J., Cook, N., & Frese, K. K. (2014) · Gastrointestinal Cancer Targets and Therapy · doi:10.2147/gictt.s58925 · Cited by 17

Resistencias al tratamiento no quirúrgico en cáncer cutáneo no melanoma. Parte II: terapia fotodinámica, vismodegib, cetuximab, metotrexato intralesional y radioterapia

Gracia‐Cazaña, T., Salazar, N., Zamarrón, A., Mascaraque, M., Lucena, S. R., & Juarranz, Á. (2016) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2016.04.020 · Cited by 17

Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib

Wang, X., Chen, K., Yu, Y., Xiang, Y., Kim, J., Gong, W., Huang, J., Shi, G., Li, Q. Y., Zhou, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22596 · Cited by 16

Current and emerging EGFR therapies for glioblastoma

Artene, Ş.-A., Tuţă, C., Dragoi, A., Alexandru, O., Purcaru, Ş. O., Tache, D. E., Dănciulescu, M. M., Boldeanu, M. V., Siloşi, C. A., & Dricu, A. (2018) · Journal of Immunoassay and Immunochemistry · doi:10.1080/15321819.2017.1411816 · Cited by 16

Single-Molecule Fluorescence Detection of the Epidermal Growth Factor Receptor in Membrane Discs

Quinn, S. D., Srinivasan, S., Gordon, J. B., He, W., Carraway, K. L., Coleman, M. A., & Schlau‐Cohen, G. S. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00089 · Cited by 16

ZRBA1, a Mixed EGFR/DNA Targeting Molecule, Potentiates Radiation Response Through Delayed DNA Damage Repair Process in a Triple Negative Breast Cancer Model

Heravi, M., Kumala, S., Rachid, Z., Jean‐Claude, B. J., Radzioch, D., & Muanza, T. M. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.01.026 · Cited by 16

Combined inhibition of the EGFR/AKT pathways by a novel conjugate of quinazoline with isothiocyanate

Tarozzi, A., Marchetti, C., Nicolini, B., D’Amico, M., Ticchi, N., Pruccoli, L., Tumiatti, V., Simoni, E., Lodola, A., Mor, M., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.04.002 · Cited by 16

Lysosome trafficking is necessary for EGF-driven invasion and is regulated by p38 MAPK and Na+/H+ exchangers

Dykes, S. S., Steffan, J. J., & Cardelli, J. A. (2017) · BMC Cancer · doi:10.1186/s12885-017-3660-3 · Cited by 17

ANXA2 could act as a moderator of EGFR-directed therapy resistance in triple negative breast cancer

Zhang, Y., Bi, J., Zhu, H., Shi, M., & Zeng, X. (2018) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2018.1484275 · Cited by 16

Emerging combination therapies to overcome resistance in EGFR-driven tumors

Ratti, M., & Tomasello, G. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000035 · Cited by 15

Serial in Vivo Imaging Using a Fluorescence Probe Allows Identification of Tumor Early Response to Cetuximab Immunotherapy

Ma, T., Liu, H., Sun, X., Gao, L., Shi, J., Zhao, H., Jia, B., Wang, F., & Liu, Z. (2014) · Molecular Pharmaceutics · doi:10.1021/mp5002944 · Cited by 15

Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib

Tang, M., Song, C., Zhang, Y., Xu, X., Wang, C., Zhang, Z., & Chen, T. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01596-5 · Cited by 15

Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice

Song, X., Cao, L., Ni, B., Wang, J., Qin, X., Sun, X., Xu, B., Wang, X., & Li, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1090500 · Cited by 15

Sym004, a Novel Anti-EGFR Antibody Mixture, Augments Radiation Response in Human Lung and Head and Neck Cancers

Huang, S., Peet, C. R., Saker, J., Li, C., Armstrong, E. A., Kragh, M., Pedersen, M. W., & Harari, P. M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0587 · Cited by 15

Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach

Lange, F. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i43.6226 · Cited by 15

EGFR immunohistochemistry as biomarker for antibody-based therapy of squamous NSCLC – Experience from the first ring trial of the German Quality Assurance Initiative for Pathology (QuIP®)

Petersen, I., Dietel, M., Geilenkeuser, W. J., Mireskandari, M., Weichert, W., Steiger, K., Scheel, A. H., Büttner, R., Schirmacher, P., Warth, A., et al. (2017) · Pathology - Research and Practice · doi:10.1016/j.prp.2017.09.021 · Cited by 15

Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer

Puvanenthiran, S., Essapen, S., Haagsma, B., Bagwan, I., Green, M., Khelwatty, S. A., Seddon, A. M., & Modjtahedi, H. (2018) · Oncotarget · doi:10.18632/oncotarget.24791 · Cited by 15

EGFR and HER2 Inhibitors as Sensitizing Agents for Cancer Chemotherapy

Barbuti, A. M., Zhang, G.-N., Gupta, P., Narayanan, S., & Chen, Z. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816435-8.00001-8 · Cited by 15

Transcriptome Profiling of Acquired Gefitinib Resistant Lung Cancer Cells Reveals Dramatically Changed Transcription Programs and New Treatment Targets

Wei, N., Song, Y., Zhang, F., Sun, Z., & Zhang, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01424 · Cited by 15

Biotherapeutic Antibodies for the Treatment of Head and Neck Cancer: Current Approaches and Future Considerations of Photothermal Therapies

Qaraghuli, M. M. A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.559596 · Cited by 15

Cell-Free DNA as a Novel Marker in Cancer Therapy

Kato, S., & Jankú, F. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.15.38 · Cited by 17

The K-Ras effector p38γ MAPK confers intrinsic resistance to tyrosine kinase inhibitors by stimulating EGFR transcription and EGFR dephosphorylation

Yin, N. B., Lepp, A., Ji, Y., Mortensen, M., Hou, S., Qi, X.-M., Myers, C. R., & Chen, G. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.779488 · Cited by 15

Synergistic Anti-Tumour Effect of Syk Inhibitor and Olaparib in Squamous Cell Carcinoma: Roles of Syk in EGFR Signalling and PARP1 Activation

Huang, D.-Y., Chen, W., Chen, C., Wu, N., & Lin, W. (2020) · Cancers · doi:10.3390/cancers12020489 · Cited by 15

Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells

Oliveras‐Ferraros, C., Massaguer, A., Carrión-Salip, D., Vázquez‐Martín, A., Cufí, S., Queralt, B., Martı́n-Castillo, B., Brunet, J., Llorens, R., & Menéndez, J. A. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9612-2 · Cited by 14

Mechanisms of resistance to EGFR targeted therapies

Hrustanovic, G., Lee, B. J., & Bivona, T. G. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.23627 · Cited by 67

Resistance mechanisms of tumour cells to EGFR inhibitors

Morgillo, F., Cantile, F., Fasano, M., Troiani, T., Martinelli, E., & Ciardiello, F. (2009) · Clinical & Translational Oncology · doi:10.1007/s12094-009-0354-6 · Cited by 19

Emerging strategies to overcome resistance to third-generation EGFR inhibitors

Shi, K., Wang, G., Pei, J., Zhang, J., Wang, J., Ouyang, L., Wang, Y., & Li, W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01311-6 · Cited by 174

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms

Yamaoka, T., Ohba, M., & Ohmori, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112420 · Cited by 156

Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy

Bianco, R., Troiani, T., Tortora, G., & Ciardiello, F. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00999 · Cited by 92